AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT03097913 — intervention group
Intervention type: DEVICE
Intervention: video-stylet
Description: recording each video-stylet endotracheal tube assembly advanced through the selected nasal cavity
Study NCT01558739 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: INC424
Description: Ruxolitinib was provided in 5 mg tablets, packaged in bottles. 15 - 20 mg (dose based on Baseline platelet count) twice daily.
Study NCT02678377 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: OnabotulinumtoxinA (Botox ®) Injections
Description: OnabotulinumtoxinA (Botox ®) is a neurotoxin, which inhibits acetylcholine release and temporarily relaxes the bladder muscle to inhibit urgency incontinence.
Study NCT02678377 — intervention group
Intervention type: DRUG
Group type: SHAM_COMPARATOR
Intervention: Saline Injections
Description: Saline will be injected into the bladder so that investigators are masked to subject randomization.
Study NCT06192966 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Food supplement
Description: Probiotic formulation containing Lactobacillus plantarum, cranberry and vitamine C for 6 months 1 capsule/day
Study NCT02037958 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Laryngeal Mask Airway-Supreme
Description: Patients who receive the LMA-S
Study NCT02037958 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Endotracheal Tube
Description: Patients who receive endotracheal intubation
Study NCT06192966 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo composed of maltodextrin for 6 months 1 capsule/day
Study NCT02054728 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: RHC and IMT
Description: Eligible patients subjected to RHC will be instructed on how to do RMT using the Threshold IMT® two days in advance. RMT will be conducted with 20-30% of individual inspiratory muscle strength, which will be measured beforehand. A single training session consists of 7 cycles with 2 min inspiratory training each, followed by a 1 min break (total duration 21 min).~The actual intervention consists of inspiratory muscle training (IMT) during right-heart catheterization for at least 2 min or as long as is necessary to measure all specified parameters.
Study NCT04017988 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Ethanol Extracts of Porphyra Tenera(PTE10)
Description: 2 times a day, 2 capsules for 1 time, after breakfast/dinner meal, for 8 week
Study NCT04017988 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo for 8 week
Study NCT01903564 — intervention group
Intervention type: DEVICE
Intervention: magnetocardiography
Description: recording of magnetic heart activity
Study NCT01903564 — intervention group
Intervention type: DEVICE
Intervention: postnatal ECG
Description: postnatal ECG
Study NCT01903564 — intervention group
Intervention type: DEVICE
Intervention: fetal echocardiography
Description: fetal echocardiography
Study NCT03518216 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: ADAPT
Description: Aim to Decrease Anxiety and Pain Treatment is a remotely delivered tailored treatment integrating mindfulness meditation and cognitive behavioral therapy. It consists of 6 sessions and blends pain and anxiety coping strategies. The first 2 sessions will be interactive with a trained psychological provider and the following 4 sessions will be web-based. Each web-based session will be followed by therapist support. The intervention is delivered through a HIPAA compliant video platform.
Study NCT03067740 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bupivacaine
Description: intraperitoneal instillation of bupivacaine 0.25% ( 2mg/kg) after excision of the appendix.
Study NCT03067740 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine
Description: intraperitoneal instillation of bupivacaine 0.25% ( 2mg/kg) plus dexmedetomidine 1mcg/kg after excision of the appendix.
Study NCT03477383 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: donor-derived cell-free DNA (dd-cfDNA)
Description: Measurement of dd-cfDNA and comparison against grade of rejection as measured by endomyocardial biopsy, taken simultaneously
Study NCT01662024 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Endoscopic gastric restrictive procedure
Description: Endoluminal gastric tissue approximation using an incisionless/per-oral endoscopic suturing device for primary gastric restrictive procedures
Study NCT02497235 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TAK-935
Description: TAK-935 oral solution.
Study NCT02497235 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: [18F]MNI-792 (tracer)
Description: \[18F\]MNI-792 injection.
Study NCT02235519 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Azilsartan 40 mg.
Description: Patients will take 40 mg of azilsartan during 12 weeks
Study NCT02235519 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Azilsartan 80 mg
Description: Patients will take 80 mg of azilsartan during 12 weeks
Study NCT04231890 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: IPI monitoring
Description: Patients in this arm will have IPI monitoring
Study NCT03613480 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Motivational Interviewing
Description: Regular sessions of Motivational Interviewing at 2 weeks and then at monthly intervals for a period of 6 months
Study NCT03400995 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AK0529
Description: A solution containing 300 mg radiolabelled AK0529.
Study NCT04172896 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Intraperitoneal Uterosacral Ligament Suspension
Description: Vaginal intraperitoneal uterosacral ligament suspension performed by transfixing the ligament, intraperitoneally, in the intermediate portion (at the level of or above ischial spine plane) with three delayed absorbable 0 sutures, performed bilaterally (three sutures per side; six sutures total).
Study NCT04314167 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lowering cholesterol concentrations by PCSK-9 inhibitor
Description: Patients will receive the PCSK9-inhibitor Evolocumab as part of routine clinical management within the indication of this drug.
Study NCT00895349 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: CT Abdomen and Pelvis scan + whole body PET-CT scan
Description: Pre-treatment scan
Study NCT00895349 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: CT Abdomen and Pelvis scan
Description: Pre-treatment scan
Study NCT00532948 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: capecitabine [Xeloda]
Description: 500mg/m2 po bid (starting dose)
Study NCT03378011 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: phototherapy
Description: phototherapy either UVA1 or topical PUVA on acral vitiligo
Study NCT01096446 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Intravenous Fat Emulsions
Description: Control Group: 0.5 grams/kg/day Experimental Group: 2 grams/kg/day
Study NCT01096446 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Intravenous Fat Emulsions
Description: Control Group: 0.5 grams/kg/day Experimental Group: 2 grams/kg/day
Study NCT02195791 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pioglitazone
Description: Pioglitazone 30mg/tab (oral) 1 tab once daily for 7 days
Study NCT02195791 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo (oral) 1 tab once daily for 7 days
Study NCT00915005 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Photon Therapy
Description: Group 1: 74 Gy 37 radiation treatments, given 5 days a week for about 7 1/2 weeks. Each daily treatment should take about 20-30 minutes to complete.
Study NCT01182246 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AXP107-11
Description: The drug substance, AXP107-11, is a crystalline form of genistein, a substance shown in literature data to target pancreatic tumor cells and also the tumor microenvironment and thus sensitizes tumors to chemotherapy. AXP107-11 is formulated in a capsule containing 2x100 mg of active substance.~A maximum of four cohorts of three to six patients each will be treated with escalating dose levels of AXP107-11 alone (two weeks) and in combination with gemcitabine (one week).~AXP107-11 capsules will be ingested orally twice daily (morning and evening) each day of the treatment period. In phase Ib, AXP107-11 will be administered once daily on the first treatment day (morning), followed by twice daily administrations continuously throughout the treatment period. When a minimum of six patients have been treated and evaluated on the maintenance dose (phase 1b), additional patients will be included directly into phase IIa.
Study NCT04526925 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Respiratory filter in-line placed with the standard mouthpiece
Description: The respiratory filter is a device that removes solid/large particles from gas
Study NCT04526925 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard mouthpiece
Description: The mouthpiece is the interface that is placed on participant's face in order to measure all the breathing physilogic responses
Study NCT04172896 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Extraperitoneal Uterosacral Ligament Suspension
Description: Vaginal extraperitoneal uterosacral ligament suspension performed by transfixing the ligament, extraperitoneally, in the intermediate portion (at the level of or above ischial spine plane) using a suture capturing device with two delayed absorbable 0 sutures, performed bilaterally (two sutures per side; four sutures total).
Study NCT00970073 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Thymoglobulin 3mg total
Description: 1.5 mg/kg induction on Day 0 and 1.5 mg/kg induction on Day 2 (total of 3 mg/kg)
Study NCT00970073 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Thymoglobulin 4.5mg total
Description: 1.5 mg/kg induction on Days 0, 2 and 4 (total 4.5 mg/kg)
Study NCT03908528 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Alpha-lipoic acid Plus Chemotherapy (doxorubicin (also known as Adriamycin) plus cyclophosphamide followed by taxol)
Description: 600 mg Alpha-lipoic acid daily (an antioxidant that's in many foods, and it's made naturally in the investigator's bodies) with four cycles of doxorubicin (also known as Adriamycin) plus cyclophosphamide followed by weekly taxol for 12 weeks..
Study NCT03908528 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo Plus Chemotherapy (doxorubicin (also known as Adriamycin) plus cyclophosphamide followed by taxol)
Description: Placebo with four cycles of doxorubicin (also known as Adriamycin) plus cyclophosphamide followed by weekly taxol for 12 weeks.
Study NCT01782755 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: L. rhamnosus GG - Probiotic
Description: Twice daily, patients will receive either 1x1010 colony forming units (CFU) of L. rhamnosus GG (Culturelle, Locin Industries Ltd) in 1 capsule or an identical placebo capsule
Study NCT01782755 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo - Microcrystalline Cellulose
Description: Placebo capsule, twice daily (containing Microcrystalline Cellulose)
Study NCT02878408 — intervention group
Intervention type: GENETIC
Group type: OTHER
Intervention: Blood sampling
Description: supplementary blood sampling for analysis of: immuno-genetic, inflammatory process, retro-viruses activity, Questionaries about environment risk factors
Study NCT01148524 — intervention group
Intervention type: BIOLOGICAL
Group type: OTHER
Intervention: No Vaccine
Study NCT01148524 — intervention group
Intervention type: BIOLOGICAL
Group type: OTHER
Intervention: rMenB+OMV-NZ
Description: Subjects who had received either rMenB+OMV-NZ or placebo at study month 6 in V72P10 study had a blood sample drawn for serological analyses at 18 months later (-1/+3 months).
Study NCT00970073 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mycophenolate mofetil
Description: 1000 mg PO/IV BID for up to 6 months
Study NCT00970073 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Mycophenolate mofetil
Description: 1000 mg PO/IV BID for up to 6 months
Study NCT00970073 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: tacrolimus 3-8
Description: Trough concentration between 3 ng/mL and 8 ng/mL starting on Day 10 and continuing beyond Day 180
Study NCT00970073 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: tacrolimus 8-12
Description: Trough concentration between 8 ng/mL and 12 ng/mL on Days 0-10; between 6 ng/mL and 12 ng/mL on Days 10-30; between 6 ng/mL and 10 ng/mL Days 31-60; between 5 ng/mL and 8 ng/mL Days 61-179; and between 3 ng/mL and 8 ng/mL beyond Day 180.
Study NCT00053573 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Myozyme
Description: 20 mg/kg to 40 mg/kg qow
Study NCT02380144 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Fresh orange fruit and pasteurized fruit juice
Study NCT01501331 — intervention group
Intervention type: DEVICE
Intervention: CRTD or ICD (Energen)
Description: RRT measurement by cardiac resynchronization therapy devices and implantable cardioverter defibrillators
Study NCT03545100 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: motor control therapy
Description: scapular muscle progressive resistive exercise(PRE)
Study NCT03545100 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: regular physical therapy
Description: transcutaneous electrical nerve stimulation(TENS), shoulder joint ROM, scapular muscle PRE
Study NCT03545100 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: regular physical therapy
Description: transcutaneous electrical nerve stimulation(TENS), shoulder joint ROM, scapular muscle PRE
Study NCT01373489 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Technology-Assisted Case Management
Description: The TACM intervention uses the FORA 2-in-1 Telehealth System for diabetes to link a case manager to poorly controlled diabetics in real time. Patients will be assigned the FORA 2-in-1 Telehealth System and provided glucose test strips to allow testing at least once a day. They will be asked to perform glucose testing and blood pressure measurement using the FORA system once daily. They will be asked to upload the measurements daily as soon as possible after the test is performed. The nurse case manager will have access to a secure server to which the uploaded measurements are stored in real time. Medications are titrated under supervision of a primary care and endocrinology physicians
Study NCT00292396 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Anti IL-12 monoclonal antibody/ABT-874
Description: Please see Arm Description for intervention description and details.
Study NCT00292396 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: 12 doses
Study NCT01083485 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxycodone/Naloxone PR 20/10mg or 10/5mg tablets
Description: Oxycodone/Naloxone prolonged release 20/10mg or 10/5mg tabs twice a day (BID) for 2.5 days (total 5 dosages)or Oxycodone 20mg
Study NCT01083485 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Oxycodone
Description: Oxycodone 20mg or 10mg BID for 2.5 days (total 5 dosages)
Study NCT00562029 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Duodenal-jejunal Bypass
Description: Patient has undergone a duodenal bypass and bypass of 60cm of proximal jejunum
Study NCT02746172 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Cochlear implant with in-situ audiometry
Study NCT04970784 — intervention group
Intervention type: OTHER
Intervention: Activities of Daily Living (ADL) questionnaire (The Katz index )
Description: For patients cared for by the geriatric sector, questionnaire will be filled in at admission D0 and by phone at D30, for the classic emergency patients questionnaire will be submitted by phone the day following the consultation D1, and D30.
Study NCT04099407 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pirfenidone
Description: Treatment consist of 600 mg tablets of a prolonged-released formulation of Pirfenidone. Patients are instructed to take medication orally, every 12 h, after breakfast and dinner.
Study NCT04099407 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Standard of care
Description: All participants will require to adhere to a standard of care including nutritional support, quarterly medical evaluation to review lab results and adjust medications, bi-annual Fibrotest, FibroScan and liver ultrasound, and annual upper-gastrointestinal endoscopy.
Study NCT01230723 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Everolimus-Eluting-Stent
Description: due randomization everolimus-eluting-stent will be implanted
Study NCT01230723 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Zotarolimus-Eluting-Stent
Description: due randomization zotarolimus-eluting-stent will be implanted
Study NCT01896336 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Zolpidem Hemitartrate
Description: Patz - 5mg sublingual zolpidem hemitartrate~1 QD~Stilnox - 10mg oral zolpidem hemitartrate~1 QD
Study NCT01896336 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Zolpidem Hemitartrate
Description: Patz - 5mg sublingual zolpidem hemitartrate~1 QD~Stilnox - 10mg oral zolpidem hemitartrate~1 QD
Study NCT02319512 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Chewing gum
Description: ChiczaTM organic chewing gum 6 pieces a day
Study NCT02319512 — intervention group
Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Glucose
Description: 12ml glucose solution (13,6g) per day
Study NCT03836703 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Feroglobin single daily use
Description: Feroglobin single daily use ( IRON FUM\&POLYSAC#1/FA/MV NO.18 162 Mg-115.2 Mg (106 Mg Iron)-1 Mg ORAL CAPSULE ) to prevent iron deficiency anemia during pregnancy from 14 weeks gestation going on.
Study NCT03836703 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Feroglobin twice daily dose
Description: Feroglobin twice daily dose ( IRON FUM\&POLYSAC#1/FA/MV NO.18 162 Mg-115.2 Mg (106 Mg Iron)-1 Mg ORAL CAPSULE ) to prevent iron deficiency anemia during pregnancy from 14 weeks gestation going on.
Study NCT02954627 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Intervention: Dietary Supplement: Intensive dietary intervention
Description: Participants receive a hypo-caloric formula diet containing 800 to 1,000 kcal/day. The formula diet consists of ready-to-use meal bars and powders to mix with water to make shakes, soups, or porridge. The weight loss programme consists of an 8-week period with full meal replacement by a standard liquid energy intake protocol. To facilitate compliance with the programme, participants will be scheduled for weekly facility-based group sessions with 6-8 participants led by a dietician. The recommendations for daily nutrient intake will be met.
Study NCT01680965 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ofatumumab
Description: Phase I: test an escalating dose of ofatumumab at cohorts of 300 mg, 700 mg, and 1000 mg given on day 0 and 14 of study.~Phase II: Ofatumumab MTD on day 0 and 14; patients will be followed for total of 24 months (months 1, 3, 6, 12 after therapy, then at 18 and 24 months following therapy)
Study NCT03252119 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: High flow humidified oxygen therapy
Description: application of high flow humidified oxygen therapy at 2l/kg/min
Study NCT04111809 — intervention group
Intervention type: BIOLOGICAL
Intervention: Blood and urine collection
Description: collected 10 mL of blood and 15 mL of urine every 2 months until 12 months
Study NCT00697359 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Implantable loop recorder (ILR)
Description: The ILR will be implanted subcutaneous following standard surgical procedure.
Study NCT02233569 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Intraperitoneal onlay mesh (IPOM) repair with the use of Phisiomesh implant and Securestrap fixation device.
Description: Laparoscopic intraperitoneal onlay mesh repair for abdominal wall hernia with the use of specially designed mesh and fixation device systems: Physiomesh (mesh implant) and Securestrap (fixation device)
Study NCT02233569 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Intraperitoneal onlay mesh (IPOM) repair with the use of Ventralight ST implant with SorbaFix fixation device.
Description: Laparoscopic intraperitoneal onlay mesh repair for abdominal wall hernia with the use of specially designed mesh and fixation device systems: Ventralight ST (mesh implant) and SofbaFix (fixation device)
Study NCT02233569 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Ventralight ST implant
Study NCT01999751 — intervention group
Intervention type: DEVICE
Intervention: MRI Scan
Description: Clinically indicated MRI scan of patients with pacemaker or implantable cardioverter-defibrillator in situ.
Study NCT00292591 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cholecalciferol (vitamin D3)
Description: randomized control trial of three vitamin D doses: 400, 2000 and 4000 IU/day
Study NCT00292591 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: cholecalciferol (vitamin D3)
Description: randomized control trial of three vitamin D doses: 400, 2000 and 4000 IU/day
Study NCT00292591 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cholecalciferol
Description: comparing vitamin D requirements of pregnant women and their fetuses from 12 weeks' gestation through pregnancy
Study NCT02233569 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: ETHICON PHYSIOMESH®